Apatinib, an oral TKI which is highly selective for and strongly inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), has shown encouraging antitumour activity and tolerability in a phase II prospective study in the R/M ACC setting (NCT02775370) [31]. This evidence concerns the gene KDR and adrenal cortex carcinoma.